-
公开(公告)号:US20110008439A1
公开(公告)日:2011-01-13
申请号:US12521410
申请日:2007-12-21
申请人: Miha Tomaz Jaklic , Rok Jurecic
发明人: Miha Tomaz Jaklic , Rok Jurecic
IPC分类号: A61K9/14 , A61K31/381
CPC分类号: A61K31/381 , A61K9/5078 , A61K9/5089 , A61K2300/00
摘要: The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt.
摘要翻译: 本发明涉及包含度洛西汀或其药学上可接受的盐的稳定药物颗粒组合物和制备该组合物的方法。 特别地,组合物包含度洛西汀盐酸盐和包含水溶性无机盐的分离层。
-
公开(公告)号:US20090093499A1
公开(公告)日:2009-04-09
申请号:US12158413
申请日:2006-12-18
IPC分类号: A61K31/505 , A61P3/06
CPC分类号: A61K31/505 , A61K9/2018 , A61K9/2866 , A61K45/06
摘要: A chemically stable formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules has been developed using the substances which stabilize against formation of degradation products: lactone and oxidation product.
摘要翻译: (E)-7- [4-(4-氟苯基)-6-异丙基-2- [甲基(甲基磺酰基)氨基]嘧啶-5-基] - (3R,5S) 二羟基庚-6-烯酸或其药学上可接受的盐用于口服使用,例如片剂,胶囊,粉剂,颗粒剂,其使用稳定反应形成降解产物的物质:内酯和氧化产物。
-
3.
公开(公告)号:US20100120868A1
公开(公告)日:2010-05-13
申请号:US12613775
申请日:2009-11-06
IPC分类号: A61K31/4439 , A61P3/10
CPC分类号: A61K9/5084 , A61K9/1623 , A61K9/1652 , A61K9/167 , A61K9/2077 , A61K31/4439 , A61K31/64 , A61K45/06 , A61K2300/00
摘要: The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process.
摘要翻译: 本发明涉及制备固体药物组合物马来酸罗格列酮的方法,其包括在干混合过程中将马来酸罗格列酮吸附到载体颗粒(C)上的步骤。
-
-